About Genomic Health (NASDAQ:GHDX)
Genomic Health, Inc., a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. The company offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the breast cancer recurrence and chemotherapy benefit. It also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy. In addition, the company provides the Oncotype DX tests for patients with ductal carcinoma in situ, a pre-invasive form of breast cancer; the Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk disease, as well as used to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score or tumor grading; and Oncotype DX AR-V7 Nucleus Detect test for men with metastatic castration-resistant prostate cancer. The company offers its products through a network of distributors. Genomic Health, Inc. has collaboration agreement with Epic Sciences, Inc.; license and development agreement with Biocartis N.V.; license agreement with Cleveland Diagnostics, Inc.; and a research collaboration agreement with Janssen Pharmaceuticals. The company was founded in 2000 and is based in Redwood City, California.
Industry, Sector and Symbol
Industry Medical laboratories
Trailing P/E Ratio4,959.00
Forward P/E Ratio105.51
Sales & Book Value
Annual Sales$340.75 million
Price / Sales5.15
Cash Flow$0.3488 per share
Price / Cash142.16
Book Value$5.41 per share
Price / Book9.17
EPS (Most Recent Fiscal Year)$0.01
Return on Equity3.15%
Return on Assets2.54%
Genomic Health (NASDAQ:GHDX) Frequently Asked Questions
What is Genomic Health's stock symbol?
Genomic Health trades on the NASDAQ under the ticker symbol "GHDX."
How were Genomic Health's earnings last quarter?
Genomic Health, Inc. (NASDAQ:GHDX) posted its quarterly earnings data on Wednesday, May, 2nd. The medical research company reported $0.13 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.05 by $0.08. The medical research company earned $92.60 million during the quarter, compared to the consensus estimate of $88.95 million. Genomic Health had a negative net margin of 1.95% and a positive return on equity of 3.15%. The firm's revenue was up 12.5% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.02) EPS. View Genomic Health's Earnings History.
When is Genomic Health's next earnings date?
What price target have analysts set for GHDX?
9 equities research analysts have issued 12 month target prices for Genomic Health's stock. Their forecasts range from $25.00 to $45.00. On average, they anticipate Genomic Health's share price to reach $33.25 in the next twelve months. View Analyst Ratings for Genomic Health.
Who are some of Genomic Health's key competitors?
Some companies that are related to Genomic Health include ELEKTA AB/ADR (EKTAY), Foundation Medicine (FMI), Natera (NTRA), RadNet (RDNT), CareDx (CDNA), InVitae (NVTA), Veracyte (VCYT), Enzo Biochem (ENZ), Miragen Therapeutics (MGEN), Celcuity (CELC), PotNetwork (POTN), Psychemedics (PMD), Fulgent Genetics (FLGT), First Choice Healthcare Solutions (FCHS) and Cancer Genetics (CGIX).
Who are Genomic Health's key executives?
Genomic Health's management team includes the folowing people:
- Ms. Kimberly J. Popovits, Chairman, CEO & Pres (Age 59)
- Dr. Steven Shak, Co-Founder, Chief Scientific Officer & Chief Medical Officer (Age 67)
- Mr. G. Bradley Cole, Chief Financial Officer (Age 62)
- Dr. Frederic G. Pla, Chief Operating Officer (Age 59)
- Mr. James J. Vaughn, Chief Commercial Officer (Age 55)
Has Genomic Health been receiving favorable news coverage?
News stories about GHDX stock have been trending somewhat positive this week, according to Accern Sentiment. Accern ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Genomic Health earned a coverage optimism score of 0.11 on Accern's scale. They also gave headlines about the medical research company an impact score of 46.55 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
Who are Genomic Health's major shareholders?
Genomic Health's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.47%), Loomis Sayles & Co. L P (1.38%), Schwab Charles Investment Management Inc. (1.22%), Point72 Asset Management L.P. (1.10%), Eagle Asset Management Inc. (0.85%) and Northern Trust Corp (0.76%). Company insiders that own Genomic Health stock include Felix Baker, Fred E Cohen, G Bradley Cole, James J Vaughn, Kimberly J Popovits, Laura Leber, Phillip G Febbo and Steven Shak. View Institutional Ownership Trends for Genomic Health.
Which institutional investors are selling Genomic Health stock?
GHDX stock was sold by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Wells Fargo & Company MN, Schwab Charles Investment Management Inc., UBS Group AG, Candriam Luxembourg S.C.A., BlackRock Inc., Loomis Sayles & Co. L P and University of Notre Dame DU Lac. Company insiders that have sold Genomic Health company stock in the last year include G Bradley Cole, James J Vaughn, Kimberly J Popovits, Laura Leber, Phillip G Febbo and Steven Shak. View Insider Buying and Selling for Genomic Health.
Which institutional investors are buying Genomic Health stock?
GHDX stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Carillon Tower Advisers Inc., Russell Investments Group Ltd., A.R.T. Advisors LLC, Algert Global LLC, Citadel Advisors LLC, GSA Capital Partners LLP and Alambic Investment Management L.P.. View Insider Buying and Selling for Genomic Health.
How do I buy shares of Genomic Health?
Shares of GHDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Genomic Health's stock price today?
One share of GHDX stock can currently be purchased for approximately $49.59.
How big of a company is Genomic Health?
Genomic Health has a market capitalization of $1.75 billion and generates $340.75 million in revenue each year. The medical research company earns $-3,850,000.00 in net income (profit) each year or $0.01 on an earnings per share basis. Genomic Health employs 863 workers across the globe.
How can I contact Genomic Health?
Genomic Health's mailing address is 301 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The medical research company can be reached via phone at 650-556-9300 or via email at [email protected]
MarketBeat Community Rating for Genomic Health (GHDX)MarketBeat's community ratings are surveys of what our community members think about Genomic Health and other stocks. Vote "Outperform" if you believe GHDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GHDX will underperform the S&P 500 over the long term. You may vote once every thirty days.